- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT03338595
Longitudinal Assessment of Exercise Capacity and Vascular Function in Patients With CF
Descripción general del estudio
Estado
Condiciones
Descripción detallada
Cystic Fibrosis (CF) is the most common fatal genetic disease in North America. The most disturbing aspect of CF is the associated premature death, most often due to respiratory complications. Clinical manifestations of CF include not only lung dysfunction, but many other systemic consequences as well. Systemic oxidative stress and exercise intolerance are established phenotypes in patients with CF. Additionally, for the first time the investigators have recently published the presence of systemic endothelial dysfunction in a cohort of young patients with CF who exhibited normal oxygen saturation and spirometric function.
Exercise intolerance, the limitation of the ability to perform exercise at the expected level, has been shown to predict mortality in patients with CF independent of lung function. Exercise capacity (VO2 peak), an objective measurement of exercise tolerance, drops approximately 5-8% per year in patients with CF. This excessive decay in exercise capacity not only leads to more pulmonary infections and deterioration of lung function, it represents a 5-8 fold decline compared to healthy sedentary adults. Preventing the excessive annual reduction in exercise capacity is essential to increasing the quality of life and longevity of patients with CF. However, a critical barrier to improving exercise capacity in CF is the investigators lack of knowledge regarding the different physiological mechanisms that contribute to exercise intolerance. It is important to emphasize that decreases in lung function (FEV1) do not always contribute to reductions in VO2 peak. Furthermore, less than 2% of patients who have an FEV1 greater than 50% predicted will have a significant drop in hemoglobin oxygen saturation (SpO2) during maximal exercise. These data suggest that mechanisms other than lung function induced hypoxemia may be contributing to exercise intolerance in patients with CF.
Tipo de estudio
Inscripción (Actual)
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Georgia
-
Augusta, Georgia, Estados Unidos, 30912
- Georgia Prevention Institute
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Descripción
Inclusion Criteria:
- Patients diagnosed with Cystic Fibrosis (homozygous deltaF508del)
- Prescribed Orkambi
- Men and women (> 18 yrs. old)
- Boys and girls (7 -17 yrs. old)
- FEV1 percent predicted > 40%
- Resting oxygen saturation (room air) >85%
- Patients with or without CFRD
- Traditional CF-treatment medications
- Clinically stable for past 28 days (no exacerbations or change in medical status)
- Healthy Controls
Exclusion Criteria:
- Children 6 yrs. old and younger
- FEV1 percent predicted < 40%
- Resting oxygen saturation (room air) < 85%
- Clinical diagnosis of heart disease
- Pulmonary artery hypertension
- Febrile illness within two weeks of visit
- Current smokers
- Currently pregnant or nursing
- Individuals on vaso-active medications (i.e. nitrates, beta blockers, ACE inhibitors, etc.)
- Use of VX-770 within 6 months prior to Visit 1
- History of solid organ transplantation
- Presence of a condition or abnormality that in the opinion of the investigator would compromise the safety of the patient or the quality of the data.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Maximal exercise capacity
Periodo de tiempo: 1 year
|
Subjects will perform the maximal exercise tests on an electronically braked cycle ergometer using the Godfrey protocol.
Expired gases will be collected using a Parvo Medics True One metabolic cart for determination of exercise capacity (VO2 peak).
|
1 year
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Flow mediated dilation
Periodo de tiempo: 1 year
|
The brachial artery FMD test will be performed according to the recent tutorial on the ultrasonic assessment of FMD and shear rate will be calculated as the stimulus of the vasodilatory response.
Briefly, subjects will lie in the supine position for 20 minutes to obtain hemodynamic steady state.
A blood pressure cuff (Hokanson) will be placed around the forearm (distal to the Doppler transducer) and rapidly inflated to 250 mmHg for 5 minutes (circulatory arrest).
Simultaneous ultrasound images of the vessel (B-mode) and Doppler waveforms will be collected 10 seconds prior to and for 2 minutes following deflation of the cuff.
|
1 year
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Ryan Harris, PhD, Augusta University
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- CF-Long
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Fibrosis quística
-
Peking Union Medical College HospitalReclutamientoFibrosis Retroperitoneal IdiopáticaPorcelana
-
San Gerardo HospitalTerminadoFibrosis pulmonar idiopática | Fibrosis cardiaca | Fibrosis ArterialItalia
-
Assistance Publique - Hôpitaux de ParisReclutamientoFibrosis Retroperitoneal IdiopáticaFrancia
-
Peking Union Medical College HospitalReclutamientoFibrosis Retroperitoneal IdiopáticaPorcelana
-
Peking Union Medical College HospitalReclutamiento
-
Peking Union Medical College HospitalReclutamientoFibrosis Retroperitoneal IdiopáticaPorcelana
-
University of ParmaDesconocidoFibrosis Retroperitoneal Idiopática | Fibrosis retroperitoneal perianeurismática | Periaortitis crónicaItalia
-
Hospital de Clinicas de Porto AlegreDesconocidoFibrosis quística | Exacerbación pulmonar de fibrosis quística | Fibrosis quística en niños | Fibrosis quística con exacerbaciónBrasil
-
Olympus Corporation of the AmericasGeisinger ClinicTerminado
-
Johns Hopkins UniversityGuerbetAún no reclutandoFibrosis miocárdicaEstados Unidos